Retatrutide Prescribed Online to Indiana Residents

Medical Weight Loss Treatment in Indiana

Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).

Key Benefits

Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
~58% hepatic fat reduction in Phase 2 sub-group analyses
Elevated basal metabolic rate via glucagon receptor agonism
Research-grade purity ≥98% with full CoA, HPLC, and MS documentation

Who is a Good Candidate?

Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.

Available for research use

Serving Indiana

From the racing culture of Indianapolis to the manufacturing heritage of Fort Wayne, Hoosiers work hard and deserve healthcare that works for them. OmniRx Health brings specialized telemedicine to Indiana—serving the young professionals of downtown Indy, the families in suburban Hamilton County, the students at Purdue and IU, and the agricultural communities that feed the nation. No more taking half a day off work just for a doctor's appointment.

Our medical providers are licensed by the Indiana Professional Licensing Agency for comprehensive telehealth services statewide.

Indiana pharmacies in Indianapolis, Fort Wayne, South Bend, and throughout the state ensure quick prescription fulfillment and delivery.

Indiana's telehealth regulations support provider practice while ensuring patient safety standards are met for virtual care delivery.

Indiana insurers provide telehealth coverage, with ongoing improvements to ensure virtual care is accessible and affordable for Hoosiers.

Frequently Asked Questions

What is retatrutide and how does it work?: Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
How does retatrutide compare to semaglutide and tirzepatide in research?: Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
Is retatrutide available for human use?: No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
Is telehealth legal in Indiana?: Yes, telehealth is legal in Indiana. The state supports virtual healthcare delivery, allowing licensed providers to offer consultations, prescribe medications, and manage patient care remotely.
Can Indiana residents get prescriptions via telehealth?: Yes, Indiana allows telehealth providers to prescribe medications following proper virtual evaluations. Prescriptions can be sent to your local pharmacy or shipped directly to your home.
Is telehealth covered by Indiana insurance?: Most Indiana health insurance plans cover telehealth visits. Coverage varies by plan, but virtual care is increasingly recognized as a standard part of healthcare delivery.